pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 15·2 min read
save

STAT+: Up and down the ladder: The latest comings and goings

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

May 15, 2026·read at STAT ↗

STAT PlusPharmalot Up and down the ladder: The latest comings and goings Manage alerts for this article Email this article Share this article By Ed SilvermanMay 15, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Hired someone new and exciting?

Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.

That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy.

Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week. This time around, we note that Basking Biosciences hired Lance Berman as chief medical officer.

Previously, he held the same role at Pulmocide.Advertisement But all work and no play can make for a dull chief medical officer. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%!

2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, jobs, Pharmaceuticals, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

Newsletter From the lab to the medicine chest, these are the must-read drug industry updates of the day Recommended Pharmalot May 15, 2026 STAT Plus: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more Exclusive May 14, 2026 STAT Plus: CDC plans to transfer monkeys to nonprofit’s sanctuary as it seeks to reduce animal testing Advertisement Pharmalot May 14, 2026 STAT Plus: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more Pharmalot May 13, 2026 STAT Plus: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more Pharmalot May 12, 2026 STAT Plus: European Union inks a draft deal to boost local production of medicines and avoid shortages Subscriber Picks

source

Reporting by STAT.

read at STAT ↗
468 words · retrieved May 15
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LILLYRISING
topics
Duchenne Muscular DystrophyObesity

related stories

  • Aug 5STAT+: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safetySTAT
  • Jul 31STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and moreSTAT
  • Jul 30STAT+: Rising oil prices can boost the cost of some medicines. One expert says it’s time to lower reliance on fossil fuelsSTAT
  • Jul 27Apnimed aspires for up to $160M IPO as sleep apnea pill launch nearsFierce Biotech
  • Jul 24STAT+: Up and down the ladder: The latest comings and goingsSTAT